INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 領航醫藥及生物科技有限公 司 承董事會命 領航醫藥及生物科技有限公司 主席 蔣年 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 股東特別大會通告 茲通告領航醫藥及生物科技有限公司（「本公司」）謹訂於二零二五年三月二十八日 （星期五）下午三時正於香港灣仔港灣道4號灣景國際二樓宴會廳1–2舉行股東特別大會， 藉以： 普通決議案 1. 委任永拓富信會計師事務所有限公司為本公司核數師，自本決議案獲採納日 期起生效直至本公司下屆股東週年大會結束為止，並授權董事會釐定其酬金。 Clarendon House 2 Church Street Hamilton HM 11 Bermuda 香港主要營業地點： 香港 灣仔 軒尼斯道145號 安康商業大廈 20樓2002室 – 1 – 附註： 於本通告日期，董事會 ...

（於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其 他註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有領航醫藥及生物科技有限公司之股份，應立即將本通函 連同隨附之代表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或 其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本通函全部或任何部 份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 (1) 建議委任核數師 及 (2) 股東特別大會通告 董事會函件載於本通函第3至第5頁。本公司謹訂於二零二五年三月二十八日（星期五） 下午三時正於香港灣仔港灣道4號灣景國際二樓宴會廳1–2舉行股東特別大會（或其任何 續會），大會通告隨附於本通函。 本通函亦隨附股東特別大會適用之 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED （股份代 號：399） 建議委任核數師 本公告由領航醫藥及生物科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則第13.51(4)條而 作出。 茲提述本公司日期為二零二四年八月十四日的公告，內容有關（其中包括）開 元信德會計師事務所有限公司辭任本公司核數師。除另行界定外，本公告所用 詞彙與該公告所界定者具有相同涵義。 本公司董事（「董事」）會（「董事會」）欣然宣佈，經參考本公司審核委員會（「審 核委員會」）的推薦建議，其已議決建議委任永拓富信會計師事務所有限公司（「永 拓富信」）為本公司新任核數師（「建議委任」），並擔任本公司核數師直至本公 司下屆股東週年大會結束為止，惟須待本公司股東（「股東」）於本公司將舉行 的股東特別大會（「股東特別大會」）上批准後，方可作 ...

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 董事名單與其角色及職能 領航醫藥及生物科技有限公司（「本公司」）董事會（「董事會」）成員載列如下：— 執行董事 高源興先生 唐榕先生 李杰鴻先生 齊淑娟女士 香港，二零二五年三月四日 請同時參閱本公告於本公司網站www.ipb.asia及www.irasia.com/listco/hk/ipb刊 載 之內容。 非執行董事 蔣年女士 （主席） 獨立非執行董事 陳偉君女士 王榮樑先生 陳金中先生 董事會設立三個委員會，包括審核委員會、薪酬委員會以及提名委員會。下表 提供各董事會成員於這些委員會所擔任的職位： | 委員會 | 董事 | 審計委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 陳偉君女士 | | 主席 | | | | 王榮樑先生 | | 委員 | 主席 | 委員 | | 陳金中先生 | | 委員 | 委員 | 委員 | | 蔣年女士 | | | 委員 | 主 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 執行董事辭任 鄭先生已確認，彼與董事會並無意見分歧，亦無有關彼辭任之任何事宜須提請 本公司股東或香港聯合交易所有限公司垂注。董事會謹此衷心感謝鄭先生於 任期內對本公司作出的寶貴貢獻。 承董事會命 領航醫藥及生物科技有限公司 主席 蔣年 香港，二零二五年三月四日 於本公告日期，董事會包括蔣年女士（主席兼非執行董事）、高源興先生（執行董事）、唐榕先 生（執行董事）、李杰鴻先生（執行董事）、齊淑娟女士（執行董事）、陳偉君女士（獨立非執行 董事）、王榮樑先生（獨立非執行董事）及陳金中先生（獨立非執行董事）。 董事會宣佈，鄭德耀先生已辭任執行董事，自二零二五年三月四日起生效。 領航醫藥及生物科技有限公司（「本公司」）董事（「董事 ...

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 非執行董事 蔣年女士 （主席） 獨立非執行董事 陳偉君女士 王榮樑先生 陳金中先生 董事會設立三個委員會，包括審核委員會、薪酬委員會以及提名委員會。下表 提供各董事會成員於這些委員會所擔任的職位： （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 董事名單與其角色及職能 領航醫藥及生物科技有限公司（「本公司」）董事會（「董事會」）成員載列如下：— 執行董事 高源興先生 唐榕先生 鄭德耀先生 李杰鴻先生 齊淑娟女士 香港，二零二五年二月十一日 請同時參閱本公告於本公司網站www.ipb.asia及www.irasia.com/listco/hk/ipb刊 載 之內容。 | 委員會 | 董事 | 審計委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 陳偉君女士 | | 主席 | | | | 王榮樑先生 | | 委員 | 主席 | 委員 | | 陳金中先生 | | 委員 | 委員 | 委員 | | 蔣年女士 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 非執行董事辭任 及 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 鄔女士及肖女士已各自確認，彼與董事會並無意見分歧，亦無有關彼等各自辭 任之任何事宜須提請本公司股東或香港聯合交易所有限公司（「聯交所」）垂注。 – 1 – (i) 鄔燕敏女士已辭任非執行董事； (ii) 肖焱女士已辭任非執行董事； (iii) 李杰鴻先生已獲委任為執行董事； (iv) 齊淑娟女士已獲委任為執行董事。 董事會謹此衷心感謝鄔女士及肖女士於任期內對本公司作出的寶貴貢獻。 委任執行董事 董事會欣然宣佈，李杰鴻先生（「李先生」）及齊淑娟女士（「齊女士」）已各自獲 委任為執行董事，自二零二五年二月十一日起生效。李先生及齊女士的履歷詳 情載列如下： 委任執行董事 董事會宣佈，自二零二五年二月十一日 ...

Financial Performance - For the six months ended September 30, 2024, the profit attributable to owners of the Company was HK$101,741,000, a decrease of 47.5% compared to HK$193,688,000 for the same period in 2023[13]. - Total comprehensive income for the period was HK$100,994,000, down from HK$192,526,000 in the previous year, reflecting a significant decline[27]. - Basic earnings per share decreased to HK$5.87 from HK$13.23, indicating a drop of 55.7% year-over-year[28]. - The Group's total comprehensive expense for the period was HK$193,688,000[90]. - The Group's revenue for the Financial Period was approximately HK$3.0 million, a decrease of approximately 18.9% compared to HK$3.7 million in the Previous Financial Period[160]. - Profit attributable to the owners of the Company for the Financial Period was approximately HK$101.7 million, down from HK$193.7 million in the Previous Financial Period[175]. Assets and Liabilities - As of September 30, 2024, net assets increased to HK$471,248,000 from HK$319,431,000 as of March 31, 2024, representing a growth of 47.5%[17]. - Current assets as of September 30, 2024, included trade receivables of HK$3,372,000, down from HK$4,905,000, indicating a decrease of 31.2%[29]. - The Company reported non-current liabilities of HK$55,618,000, a decrease from HK$671,991,000, showing a significant reduction in financial obligations[17]. - The Company’s total equity attributable to owners was HK$458,920,000, compared to HK$930,168,000 in the previous period, reflecting a decrease of 50.7%[17]. - The accumulated losses of the Group amounted to HK$801,457,000 as of 30 September 2024[101]. - The Group's total equity as of 30 September 2024 was HK$1,119,294,000[99]. - The Group has outstanding loans from a substantial shareholder and a former associate totaling approximately HK$25,487,000, which are due for repayment within the next 12 months[124]. - As of 30 September 2024, the Group has net current liabilities of approximately HK$846,358,000, including outstanding convertible bonds of HK$768,471,000 maturing in July 2025[107]. - The Group's current liabilities as of September 30, 2024, amounted to approximately HK$846,358,000, which includes convertible bonds of HK$768,471,000 due in July 2025[124]. Clinical Trials and Product Development - The management is working on a Clinical Trial for an oral insulin product, expected to launch in Q1 2026, with no negative feedback reported so far[111]. - The Group is currently in the third phase of clinical trials for its oral insulin product, with commercialization expected to generate future cash flows contingent on successful trial outcomes and necessary regulatory approvals[142]. - Approximately 480 patients have been enrolled in the Clinical Trial, which commenced in July 2020, and patient recruitment will continue[180]. - The oral insulin product is expected to be launched in the market by the first quarter of 2026, with significant demand anticipated due to the growing diabetic population in the PRC[166]. - The product will be the first oral insulin drug available in the market and is expected to be protected for 5 years under current PRC regulations[166]. - The in-process research and development project for the oral insulin product has a carrying value of HK$1,373 million recorded as an intangible asset[176]. - The Group will inject additional resources into the clinical trial of the oral insulin product to facilitate its development[161]. - The management performed an impairment assessment of intangible assets, concluding that the recoverable amount exceeds the carrying value, thus no impairment is necessary[181]. - The Company is focused on ensuring that its in-process R&D aligns with its commercialization schedule[185]. - The Company has established a project team to oversee the development and commercialization of new products[185]. Financing and Support - The Company has received financial support from a substantial shareholder, who will not demand repayment of approximately HK$6,800,000 for at least 12 months[111]. - The management is actively seeking other financing and borrowing opportunities[111]. - A shareholders' loan agreement was entered into for a total sum of HK$20 million to support the operation of the Clinical Trials[183]. - The subscription price for the convertible bonds will be offset against the outstanding shareholder's loans of HK$55,500,000[190]. - The Group's cash flow from financing activities showed a net decrease of HK$2,630,000 for the six months ended September 30, 2024, compared to a decrease of HK$511,000 in the previous period[140]. Compliance and Governance - The Company has maintained compliance with the Model Code for Securities Transactions by Directors throughout the financial period[2]. - The Group's financial statements have been prepared on a going concern basis, with significant uncertainties regarding the ability to generate cash flows from the successful completion of clinical trials[128]. - The application of new and amended HKFRSs in the current period has had no material impact on the interim condensed consolidated financial information[134]. - The Group has not early adopted any new and revised HKFRSs that have been issued but are not yet effective[134]. Market and Business Conditions - The decrease in revenue was mainly due to unfavorable business conditions affecting the trading of beauty equipment and products segment[160]. - The Group has two reportable segments: trading of beauty equipment and products in Hong Kong, and research and development and commercialization of products[132]. - The Group's major trading products are beauty equipment and beauty products, which represent the primary source of revenue[184]. - There were no significant market expansions or acquisitions reported in the latest financial results[1]. - The Company has not disclosed any new product launches or technological advancements during this reporting period[1]. Convertible Bonds - On July 27, 2023, the Company conditionally agreed to issue convertible bonds amounting to HK$55,500,000, with a conversion price set at HK$0.211 per share[186]. - As of August 15, 2023, the total outstanding convertible bonds amounted to HK$359,600,000, with amendments to certain terms and conditions agreed upon[195]. - The amendment to the convertible bonds was approved on May 24, 2024, and completed on June 21, 2024[200]. - The conversion price for certain convertible bonds due in October and December 2023 was amended from HK$0.40 to HK$0.202[198]. - The maturity date for some convertible bonds due in December 2024 and April 2025 will not be extended[198]. - The Group's cash and cash equivalents at the end of the period were affected by foreign exchange rate changes, resulting in an increase of HK$3,075,000[140].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 自願公告 有關可能投資事項 之主要條款書 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二四年十二月十日，本公司與投資人訂立主要條 款書，據此，投資人建議透過本公司將予委任的證券公司以先舊後新配售及╱ 或新股份配售方式收購本公司若干佔比的股份。 根據主要條款書進行可能投資事項須待簽立正式協議後方告落實。本公司 將於訂立正式協議時另行刊發公告。 可能投資事項須待簽立正式協議後方告落實。因此，可能投資事項可能或 未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司有意投 資者於買賣本公司股份時務請審慎行事。 – 1 – 緒言 董事會欣然宣佈，於二零二四年十二月十日，本公司與投資人訂立主要條款書， 據此，投資人建議 ...

Financial Performance - Revenue for the six months ended September 30, 2024, was HKD 3,029,000, compared to HKD 3,727,000 for the same period in 2023, representing a decrease of approximately 18.8%[2] - Gross profit for the same period was HKD 307,000, down from HKD 380,000 in 2023, indicating a decline of about 19.2%[2] - The company reported a profit before tax of HKD 100,966,000, a decrease of 47.6% from HKD 192,577,000 in the previous year[5] - The total comprehensive income for the period was HKD 100,994,000, compared to HKD 192,526,000 in the previous year, reflecting a decline of approximately 47.7%[5] - Basic earnings per share decreased to HKD 5.87 from HKD 13.23, a drop of about 55.7%[5] - The after-tax segment profit from the beauty equipment and product trading division was HKD 281,000, down from HKD 359,000 in the previous year, while the R&D division reported a loss of HKD 1,301,000 compared to a loss of HKD 2,552,000 in 2023[24] - The total comprehensive profit for the period was HKD 100,966,000, a decrease from HKD 192,577,000 in the same period last year[24] - Basic earnings attributable to the company's owners for the six months ended September 30, 2024, were HKD 101,741,000, compared to HKD 193,688,000 in 2023[30] - The company incurred financial expenses of HKD 116,240,000, a decrease from HKD 131,478,000 in the previous year[26] - The company reported a loss per share of HKD 6,790 for the six months ended September 30, 2024, compared to a loss of HKD 42,320 in the previous year[30] - The profit attributable to the company's owners was approximately HKD 101,700,000, down from HKD 193,700,000 in the previous fiscal period, primarily due to non-cash items related to convertible bonds[71] Assets and Liabilities - As of September 30, 2024, the net current liabilities amounted to HKD 846,358,000, including convertible bonds of HKD 768,471,000 due in July 2025[12] - The total assets less current liabilities were reported at HKD 526,866,000 as of September 30, 2024[7] - As of September 30, 2024, trade receivables amounted to HKD 3,372,000, a decrease from HKD 4,905,000 as of March 31, 2024[36] - Trade payables as of September 30, 2024, totaled HKD 2,388,000, an increase from HKD 1,853,000 as of March 31, 2024[37] - The company has issued convertible bonds with a total principal amount of HKD 768,471,000 as of September 30, 2024, compared to HKD 911,150,000 as of March 31, 2024[39] - The fair value of the equity component of the convertible bonds issued in 2013 was HKD 671,267,000[45] - The company has converted HKD 20,000,000 of the convertible bonds into 99,009,900 shares as of September 10, 2024[46] - The aging analysis of trade receivables shows that over 90 days receivables decreased from HKD 3,223,000 to HKD 2,279,000[36] - The company has a credit period of 90 days for trade receivables granted to customers[36] - The company's current assets to current liabilities ratio was 0.007 as of September 30, 2024, compared to 0.03 as of March 31, 2024, indicating a decline in liquidity[89] - The capital debt ratio as of September 30, 2024, was 0.66, down from 0.77 as of March 31, 2024, based on total liabilities of approximately HKD 907.6 million and total assets of approximately HKD 1,378.9 million[89] Research and Development - The company is currently developing an oral insulin product, which is in Phase III clinical trials, with commercialization expected in Q1 2026[12] - The company is engaged in the R&D of an oral insulin product, with a collaboration agreement with Tsinghua University extended until June 30, 2027[33] - Approximately 480 patients have been recruited for clinical trials, with expectations for the product to be launched in the first quarter of 2026[75] - The company anticipates that the oral insulin product will generate stable revenue and profit due to increasing demand from diabetes patients in China and being the first oral insulin product on the market[75] - The company entered into a shareholder loan agreement to provide a total of HKD 20,000,000 to support clinical trial operations[76] - The company believes there is no need to recognize impairment for the R&D process based on recoverable amount estimates[35] - The cash flow forecast for the R&D process assumes a discount rate of 1.5% and a 10-year economic benefit period[33] - The company is currently conducting R&D on an oral insulin product, with an intangible asset value of HKD 1,373,000,000 recorded on the balance sheet[73] Financing and Support - The company has received written confirmations from major shareholders and affiliates regarding financial support for upcoming obligations[14] - The company is exploring additional financing and borrowing opportunities to support its operations[16] - The company has issued convertible bonds with a principal amount of HKD 55,500,000, with a zero percent interest rate and a maturity date ten years from the issuance date[80] - As of August 15, 2023, the total principal amount of outstanding convertible bonds was HKD 359,600,000, with amendments made to extend the maturity date to twenty years from the issuance date[82] - As of September 30, 2024, the company's total borrowings amounted to approximately HKD 895.3 million, down from approximately HKD 1,054.2 million as of March 31, 2024, reflecting a reduction in debt levels[87] - The company has not pledged any assets as of September 30, 2024, maintaining a position of no asset encumbrance[92] - The company has not utilized any financial instruments to hedge foreign exchange risks during the fiscal period, maintaining a cautious strategy[93] Dividend Policy - The company did not declare or propose any dividends during the interim period, consistent with the previous year[28] - The company has not established a dividend policy, considering its financial condition and market conditions for future development[100] Business Environment and Strategy - Management expects the current business environment for beauty equipment and products to improve and plans to diversify the product range for higher profit margins[78] - Revenue from the beauty equipment and product trading segment was approximately HKD 3,000,000, reflecting an 18.9% decrease from the previous period's revenue of approximately HKD 3,700,000, attributed to an unfavorable business environment[72] - The company has not purchased or sold any property, plant, and equipment during the six months ended September 30, 2024[32]